

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
1	<b>Didactică și profesională</b>	<b>1.1. cărți și capitol în cărți de specialitate (cu ISBN) – autor / coautor</b>	<b>Criterii obligatorii:</b> 1 capitol in tratat internațional = 1 carte națională; 1 carte internațională = 3 cărți naționale <b>Profesor – 2 cărți (din care una ca prim autor sau autor unic) sau 6 capitole în tratate, de la ultima promovare</b>		
			<b>Îndeplinire:</b>	<p>Internaționale</p> <p><b>Capitole de carte:</b></p> <ul style="list-style-type: none"> <li>Ioana Agache - Best Buys for asthma prevention and control în Global Atlas of Asthma, 2013, European Academy of Allergy and Clinical Immunology</li> <li>Ioana Agache, A. Cezmi - Endotype of Allergic disease în Akdis, CA, Agache I, Global Atlas of Allergy, 2014, European Academy of Allergy and Clinical Immunology</li> <li>Ioana Agache – Hipersensitivitate pneumonitis în Akdis, CA, Agache I, Global Atlas of Allergy, 2014, European Academy of Allergy and Clinical Immunology</li> <li>Ioana Agache – Phenotypes and endotypes of allergic rhinitis în Akdis, CA, Hellings, P, Agache I, Global Atlas of Allergic Rhinitis and Chronic Rhinosinusitis, 2015, European Academy of Allergy and Clinical Immunology</li> </ul> <p>Nationale</p> <p><b>Cărți:</b></p> <ul style="list-style-type: none"> <li>Gheorghită Emanuel, Brumar Ioana, Imunologie. Vol I, 1998, Reprografia Universității "Transilvania" Brașov, 105 pag</li> <li>Mariana Rădoi, Ioana Agache, T. Alexandru, Pneumologie Vol I, 1999, Reprografia Universității "Transilvania" Brașov, 200 pag</li> </ul>	

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<ul style="list-style-type: none"> <li>Mariana Rădoi, Ioana Agache, Diana Țiņ, Patologia Trombotică. Date actuale, 2007, Editura Lux Libris, Brașov, 209 pag</li> <li>Agache Ioana, Astmul - de la noi mecanisme patogenice până la noi metode de terapie, 2008, Editura Lux Libris, Brașov (unic autor)</li> </ul> <p><b>Capitole de carte:</b></p> <ul style="list-style-type: none"> <li>Agache Ioana, Rădoi Mariana - Boli pulmonare interstițiale în „Pneumologie Clinică” sub redacția M. Rădoi, Vol. I, 1999, Editura Concordia, pg. 139-200</li> <li>Rădoi Mariana, Agache Ioana, Astmul în „Pneumologie Clinică” sub redacția M. Rădoi, Vol. I, 1999, Editura Concordia, pg. 75-138</li> <li>Rădoi Mariana, Agache Ioana, <i>Reacția inflamatorie în ateroscleroză – date actuale</i>, în „Progrese în cardiologie” sub redacția L. Gherasim, 2002, Editura Infomedica, pg. 337-399</li> </ul>
	<b>1.2. cărți și capitole în cărți de specialitate (cu ISBN) - coordonator</b>		<b>Îndeplinire:</b>	<p>Internaționale</p> <ul style="list-style-type: none"> <li>Akdis, CA, Agache I, Global Atlas of Asthma, 2013, European Academy of Allergy and Clinical Immunology</li> <li>Akdis, CA, Agache I, Global Atlas of Allergy, 2014, European Academy of Allergy and Clinical Immunology</li> <li>Akdis, CA, Hellings, P, Agache I, Global Atlas of Allergic Rhinitis and Chronic Rhinosinusitis, 2015, European Academy of Allergy and Clinical Immunology</li> <li>Agache I, Helling P. Implementing Precision Medicine In Best Practices Of Chronic Airway Disease due to be published by Elsevier in November 2017</li> <li>EAACI Food Allergy and Anaphylaxis Guidelines, 2014, Membru in Editorial Bord</li> </ul> <p>Naționale</p>	

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
2	<b>Cercetare</b>	<b>2.1. articole in extenso in reviste cotate ISI Thomson Reuters</b>	<b>Criterii obligatorii:</b> articole in reviste cu factor de impact, in calitate de autor principal, <b>de la ultima promovare: minim 6 articole</b>	16 Artic. ISI	<ol style="list-style-type: none"> <li><i>Agache I, Duca L, Anghel M, Pamfil G. Antinuclear antibodies in asthma patients- a special asthma phenotype? Iran J Allergy Asthma Immunol. 2009;8(1):49-52. FI:0,0968, <a href="http://ijaai.tums.ac.ir/index.php/ijaai/article/view/233">http://ijaai.tums.ac.ir/index.php/ijaai/article/view/233</a></i></li> <li><i>Agache I, Ciobanu C, Agache C, Anghel M. Increased serum IL-17 is an independent risk factor for severe asthma. Respir Med. 2010;104(8):1131-7 FI:2,525 <a href="http://www.resmedjournal.com/article/S0954-6111(10)00088-0/abstract">http://www.resmedjournal.com/article/S0954-6111(10)00088-0/abstract</a></i></li> <li><i>Agache I, Ciobanu C. Risk factors and asthma phenotypes in children and adults with seasonal allergic rhinitis. Phys Sportsmed. 2010;38(4):81-6. FI: 1,489 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21150146">https://www.ncbi.nlm.nih.gov/pubmed/21150146</a></i></li> <li><i>Agache I, Akdis C, Jutel M, Virchow JC. Untangling asthma phenotypes and endotypes. Allergy. 2012;67(7):835-46 FI: 5,83 <a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1398-9995.2012.02832.x/pdf">http://onlinelibrary.wiley.com/doi/10.1111/j.1398-9995.2012.02832.x/pdf</a></i></li> <li><i>Agache I, Ciobanu C. Predictive value of lung function trend and FeNO for difficult asthma in children. J Investig Allergol Clin Immunol. 2012;22(6):419-26 FI: 1,887, <a href="http://www.jiaci.org/summary/vol22-issue6-num915">http://www.jiaci.org/summary/vol22-issue6-num915</a></i></li> <li><i>Agache IO. From phenotypes to endotypes to asthma treatment. Curr Opin Allergy Clin Immunol. 2013;13(3):249-56 FI: 3,659, <a href="http://journals.lww.com/co-allergy/toc/2013/06000">http://journals.lww.com/co-allergy/toc/2013/06000</a></i></li> <li><i>Agache I, Ryan D, Rodriguez MR, Yusuf O, Angier E, Jutel M. Allergy management in primary care across European countries - actual status. Allergy. 2013; 68(7): 836-43 FI: 5,995, <a href="http://onlinelibrary.wiley.com/doi/10.1111/all.12150/pdf">http://onlinelibrary.wiley.com/doi/10.1111/all.12150/pdf</a></i></li> <li>Jutel M, Angier L, Palkonen S, Ryan D, Sheikh A, Smith H, Valovirta E, Yusuf O,</li> </ol>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>van Wijk RG, <i>Agache I. Improving allergy management in the primary care network-a holistic approach</i>. Allergy. 2013; 68(11):1362-9. <i>FI: 5,995</i>  <a href="http://onlinelibrary.wiley.com/doi/10.1111/all.12258/pdf">http://onlinelibrary.wiley.com/doi/10.1111/all.12258/pdf</a></p> <p>9. Muraro A*, <i>Agache I*</i>, Clark A*, Sheikh A, Roberts G, Akdis CA, et al; <i>European Academy of Allergy and Clinical Immunology (EAACI) food allergy and anaphylaxis guidelines: managing patients with food allergy in the community</i>. Allergy. 2014;69(8):1046-57 <i>FI: 6,028; *Joint first co-authorship</i>  <a href="http://onlinelibrary.wiley.com/doi/10.1111/all.12441/full">http://onlinelibrary.wiley.com/doi/10.1111/all.12441/full</a></p> <p>10. Jutel M, Papadopoulos NG, Gronlund H, Hoffman HJ, Bohle B, Hellings P, Braunstahl GJ, Muraro A, Schmid-Grendelmeier P, Zuberbier T, <i>Agache I. Recommendations for the allergy management in the primary care</i>. Allergy. 2014;69(6):708-18, <i>FI: 6,028</i>  <a href="http://onlinelibrary.wiley.com/doi/10.1111/all.12382/full">http://onlinelibrary.wiley.com/doi/10.1111/all.12382/full</a></p> <p>11. <i>Agache I</i>, Sugita K, Morita H, Akdis M, Akdis CA. <i>The Complex Type 2 Endotype in Allergy and Asthma: From Laboratory to Bedside</i>. Curr Allergy Asthma Rep. 2015;15(6):29, DOI: 10.1007/s11882-015-0529-x, <i>FI: 3,127</i>  <a href="http://link.springer.com/article/10.1007/s11882-015-0529-x">http://link.springer.com/article/10.1007/s11882-015-0529-x</a></p> <p>12. <i>Agache I</i>, Bilò M, Braunstahl GJ, Delgado L, Demoly P, Eigenmann P, Gevaert P, Gomes E, Hellings P, Horak F, Muraro A, Werfel T, Jutel M. <i>In vivo diagnosis of allergic diseases-allergen provocation tests</i>. Allergy. 2015;70(4):355-65, <i>FI: 6,335</i>  <a href="http://onlinelibrary.wiley.com/doi/10.1111/all.12586/full">http://onlinelibrary.wiley.com/doi/10.1111/all.12586/full</a></p> <p>13. <i>Agache I</i>, Akdis CA. <i>Endotypes of allergic diseases and asthma: An important step in building blocks for the future of precision medicine</i>. Allergol Int. 2016; 65(3):243-52. <i>FI: 2,355</i>  <a href="http://www.sciencedirect.com/science/article/pii/S132389301630048X">http://www.sciencedirect.com/science/article/pii/S132389301630048X</a></p> <p>14. <i>Agache I</i>, Strasser DS, Klenk A, Agache C, Farine H, Ciobanu C, Groenen PM,</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>Akdis CA. <i>Serum IL-5 and IL-13 consistently serve as the best predictors for the blood eosinophilia phenotype in adult asthmatics</i>. Allergy. 2016;71(8):1192-202, <i>FI: 6,335</i> <a href="http://onlinelibrary.wiley.com/doi/10.1111/all.12906/full">http://onlinelibrary.wiley.com/doi/10.1111/all.12906/full</a></p> <p>15. Muraro A, Lemanske RF, Hellings PW, Akdis CA, Bieber T, Casale TB, Jutel M, Ong PY, Poulsen LK, Schmid-Grendelmeier P, Simon HU, Seys SF, <i>Agache I</i>. <i>Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis—PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma &amp; Immunology</i>. J Allergy Clin Immunol. 2016;137(5):1347-58 <i>FI: 12,485</i> <a href="http://www.jacionline.org/article/S0091-6749(16)00456-5/fulltext">http://www.jacionline.org/article/S0091-6749(16)00456-5/fulltext</a></p>
		<p><b>2.2. articole in extenso in reviste si volumele unor manifestări științifice indexate ISI sau in alte BDI</b></p>	<p><b>Criterii obligatorii:</b>  <b>Profesor – minim 25 articole, din care 5 de la ultima promovare</b>  <b>1 articol ISI cu I.F. &lt; 1 = 3 articole in reviste indexate BDI dar nu si invers</b>  <b>1 articol ISI cu I.F. ≥ 1 = 5 articole in reviste indexate BDI dar nu si invers (I.F. = impact factor)</b></p>	<p><b>Îndeplinire:</b> 33 artic. de la ultima promovare, din care 22 articole in reviste ISI cu FI variind intre 0,1 și 12,485</p>	<p>1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, <i>Agache I</i>, et al. <i>Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)</i>. Allergy. 2008;63 Suppl 86:8-160 <i>FI: 6,204</i>, <a href="http://www.whiar.org/docs/ARIA_WR_08_View_WM.pdf">http://www.whiar.org/docs/ARIA_WR_08_View_WM.pdf</a></p> <p>2. Fantin S, Maspero J, Bisbal C, <i>Agache I</i>, Donado E, Borja J, Mola O, Izquierdo I; international Rupaadine study group. <i>A 12-week placebo-controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis</i>. Allergy. 2008;63(7):924-31 <i>FI:6,204</i>, <a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1398-9995.2008.01668.x/full">http://onlinelibrary.wiley.com/doi/10.1111/j.1398-9995.2008.01668.x/full</a></p> <p>3. Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, <i>Agache I</i>, Fouquert L, Roger A, Sologuren A, Valiente R; Bilastine International Working Group.</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p><i>Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study.</i> Clin Exp Allergy. 2009;39(9):1338-47 <i>FI: 4,084</i>  <a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2222.2009.03257.x/full">33http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2222.2009.03257.x/full</a></p> <p>4. Bousquet J; Khaltaev N; Cruz AA; Denburg J; Fokkens W; Togias A; Zuberbier T; Baena-Cagnani C; Canonica GW; van Weel C; <i>Agache I</i>; Ait-Khaled N; Bachert C; Blaiss M; Bonini S; Boulet LP; Bousquet PJ; Camargos P; Carlsen KH; Custovic A; Chen Y; Dahl R; Demoly P; Douagui H; Durham S; van Wijk RG; Kalayci O; Kaliner M; Kim YY; Kowalski ML; Kuna P; Lemiere C; Lan LTT; Li J; Lockey R; Mavale S; Meltzer EO; Mohammad Y; Mullol J; Naclerio R; O'Hehir R; Ohta K; Ouedraogo S; Palkonen S; Papadopoulos N; Passalacqua G; Pawankar R; Popov T; Rabe K; Rosado-Pinto J; Scadding G; Simons FER; Toskala E; Valovirta E; van Cauwenberge P; Wang DY; Wickman M; Yawn B; Yorgancioglu A; Yusuf O; Zar H, <i>ARIA update 2008: Allergic rhinitis and its effect on asthma</i>, Allergologie, 2009, 32(8), 306-319 <i>FI:0,120</i>  <a href="http://discovery.ucl.ac.uk/1305640">http://discovery.ucl.ac.uk/1305640</a></p> <p>5. Bousquet J, Schünemann HJ, Zuberbier T, Bachert C, Baena-Cagnani CE, Bousquet PJ, Brozek J, Canonica GW, Casale TB, Demoly P, Gerth van Wijk R, Ohta K, Bateman ED, Calderon M, Cruz AA, Dolen WK, Haughney J, Lockey RF, Lötvall J, O'Byrne P, Spranger O, Togias A, Bonini S, Boulet LP, Camargos P, Carlsen KH, Chavannes NH, Delgado L, Durham SR, Fokkens WJ, Fonseca J, Haahtela T, Kalayci O, Kowalski ML, Larenas-Linnemann D, Li J, Mohammad Y, Mullol J, Naclerio R, O'Hehir RE, Papadopoulos N, Passalacqua G, Rabe KF, Pawankar R, Ryan D, Samolinski B, Simons FE, Valovirta E, Yorgancioglu A, Yusuf OM,</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p><i>Agache I, et al, WHO Collaborating Center of Asthma and Rhinitis (Montpellier). Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. Allergy. 2010; 65(10):1212-21. FI: 6,297</i>  <a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1398-9995.2010.02439.x/full">http://onlinelibrary.wiley.com/doi/10.1111/j.1398-9995.2010.02439.x/full</a></p> <p>6. Papadopoulos NG, Christodoulou I, Rohde G, <i>Agache I</i>, Almqvist C, Bruno A, et al. <i>Viruses and bacteria in acute asthma exacerbations-a GA2LEN-DARE systematic review. Allergy 2011;66(4):458-68. FI: 6,271</i>  <a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1398-9995.2010.02505.x/full">http://onlinelibrary.wiley.com/doi/10.1111/j.1398-9995.2010.02505.x/full</a></p> <p>7. Bousquet J, Schünemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C, Bonini S, Boulet LP, Bousquet PJ, Brozek JL, Canonica GW, Casale TB, Cruz AA, Fokkens WJ, Fonseca JA, van Wijk RG, Grouse L, Haahtela T, Khaltaev N, Kuna P, Lockey RF, Lodrup Carlsen KC, Mullol J, Naclerio R, O'Hehir RE, Ohta K, Palkonen S, Papadopoulos NG, Passalacqua G, Pawankar R, Price D, Ryan D, Simons FE, Togias A, Williams D, Yorgancioglu A, Yusuf OM, Aberer W, Adachi M, <i>Agache I</i>, et al; World Health Organization Collaborating Center for Asthma and Rhinitis. <i>Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol. 2012;130(5):1049-62 FI: 12,047</i>  <a href="http://www.jacionline.org/article/S0091-6749(12)01306-1/fulltext">http://www.jacionline.org/article/S0091-6749(12)01306-1/fulltext</a></p> <p>8. Bousquet J, Anto JM, Demoly P, Schünemann HJ, Togias A, Akdis M, Auffray C, Bachert C, Bieber T, Bousquet PJ, Carlsen KH, Casale TB, Cruz AA, Keil T, Lodrup Carlsen KC, Maurer M, Ohta K, Papadopoulos NG, Roman Rodriguez M, Samolinski B, <i>Agache I</i>, et al. WHO Collaborating Center for Asthma and Rhinitis, <i>Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL-GA2LEN-ARIA position paper. Int Arch Allergy Immunol. 2012;158(3):216-31. FI: 2.677, http://www.karger.com/Journal/Issue/256844</i></p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>9. Moreira A, Bonini M, Garcia-Larsen V, Bonini S, Del Giacco SR, <i>Agache I</i>, Fonseca J, Papadopoulos NG, Carlsen KH, Delgado L, Haahtela T. <i>Weight loss interventions in asthma: EAACI evidence-based clinical practice guideline (part I)</i>. Allergy. 2013; 68(4):425-39. <i>FI: 5,995</i>  <a href="http://onlinelibrary.wiley.com/doi/10.1111/all.12106/pdf">http://onlinelibrary.wiley.com/doi/10.1111/all.12106/pdf</a></p> <p>10. Jutel M, Van de Veen W, <i>Agache I</i>, Azkur KA, Akdis M, Akdis CA. <i>Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development</i>. Allergol Int. 2013;62(4):425-33. <i>FI: 2,355</i>  <a href="http://www.sciencedirect.com/science/article/pii/S1323893015301611">http://www.sciencedirect.com/science/article/pii/S1323893015301611</a></p> <p>11. Bousquet J, Addis A, Adcock I, <i>Agache I</i>, et al. (European Innovation Partnership on Active and Healthy Ageing, Action Plan B3; Mechanisms of the Development of Allergy, WP 10; Global Alliance against Chronic Respiratory Diseases), <i>Integrated care pathways for airway diseases (AIRWAYS-ICPs)</i>. Eur Respir J. 2014;44(2):304-23 <i>FI: 7,636</i>  <a href="https://ec.europa.eu/eip/ageing/sites/eipaha/files/results_attachments/erj-00146-2014_erj44-2-press.pdf">https://ec.europa.eu/eip/ageing/sites/eipaha/files/results_attachments/erj-00146-2014_erj44-2-press.pdf</a></p> <p>12. de Silva D, Geromi M, Halken S, Host A, Panesar SS, Muraro A, Werfel T, Hoffmann-Sommergruber K, Roberts G, Cardona V, Dubois AE, Poulsen LK, Van Ree R, Vlieg-Boerstra B, <i>Agache I</i>, Grimshaw K, O'Mahony L, Venter C, Arshad SH, Sheikh A; EAACI Food Allergy and Anaphylaxis Guidelines Group. <i>Primary prevention of food allergy in children and adults: systematic review</i>. Allergy. 2014; 69(5):581-9 <i>FI: 6,028</i>  <a href="http://onlinelibrary.wiley.com/doi/10.1111/all.12334/full">http://onlinelibrary.wiley.com/doi/10.1111/all.12334/full</a></p> <p>13. de Silva D, Geromi M, Panesar SS, Muraro A, Werfel T, Hoffmann-Sommergruber K, Roberts G, Cardona V, Dubois AE, Halken S, Host A, Poulsen LK, Van Ree R, Vlieg-Boerstra BJ, <i>Agache I</i>, Sheikh A; EAACI Food</p>



**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>Allergy and Anaphylaxis Guidelines Group. <i>Acute and long-term management of food allergy: systematic review</i>. Allergy. 2014;69(2):159-67. <i>FI: 6,028</i>  <a href="http://onlinelibrary.wiley.com/doi/10.1111/all.12314/full">http://onlinelibrary.wiley.com/doi/10.1111/all.12314/full</a></p> <p>14. Bousquet J, Schunemann HJ, Fonseca J, Samolinski B, Bachert C, Canonica GW, Casale T, Cruz AA, Demoly P, Hellings P, Valiulis A, Wickman M, Zuberbier T, Bosnic-Anticevitch S, Bedbrook A, Bergmann KC, Caimmi D, Dahl R, Fokkens WJ, Gisle I, Lodrup Carlsen K, Mullol J, Muraro A, Palkonen S, Papadopoulos N, Passalacqua G, Ryan D, Valovirta E, Yorgancioglu A, Aberer W, <i>Agache I</i>, et al. <i>MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation</i>. Allergy. 2015; 70(11):1372-92. <i>FI: 6,335</i>  <a href="http://onlinelibrary.wiley.com/doi/10.1111/all.12686/full">http://onlinelibrary.wiley.com/doi/10.1111/all.12686/full</a></p> <p>15. Fleischer DM, Sicherer S, Greenhawt M, Campbell D, Chan E, Muraro A, Halken S, Katz Y, Ebisawa M, Eichenfield L, Sampson H, Lack G, Du Toit G, Roberts G, Bahnson H, Feeney M, Hourihane J, Spergel J, Young M, As'aad A, Allen K, Prescott S, Kapur S, Saito H, <i>Agache I</i>, Akdis CA, Arshad H, Beyer K, Dubois A, Eigenmann P, Fernandez-Rivas M, Grimshaw K, Hoffman-Sommergruber K, Host A, Lau S, O'Mahony L, Mills C, Papadopoulos N, Venter C, Agmon-Levin N, Kessel A, Antaya R, Drolet B, Rosenwasser L. <i>Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants</i>.</p> <ul style="list-style-type: none"> <li>• J Allergy Clin Immunol. 2015;136 (2): 258-61 <i>FI: 12,485</i>  <a href="http://www.jacionline.org/article/S0091-6749(15)00785-X/fulltext">http://www.jacionline.org/article/S0091-6749(15)00785-X/fulltext</a></li> <li>• Pediatrics, 2015, 136(3), 600-604, <i>FI: 5,196</i>  <a href="http://pediatrics.aappublications.org/content/136/3/600">http://pediatrics.aappublications.org/content/136/3/600</a></li> <li>• Pediatric Dermatology, 2015, 33(1), 102-105 <i>FI: 1,163</i></li> </ul>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<ul style="list-style-type: none"> <li>• Allergy. 2015 Oct;70(10):1193-5  <a href="http://onlinelibrary.wiley.com/doi/10.1111/all.12687/full">http://onlinelibrary.wiley.com/doi/10.1111/all.12687/full</a></li> </ul> <p>16. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, Cox L, Demoly P, Frew AJ, O'Hehir R, Kleine-Tebbe J, Muraro A, Lack G, Larenas D, Levin M, Nelson H, Pawankar R, Pfaar O, van Ree R, Sampson H, Santos AF, Du Toit G, Werfel T, Gerth van Wijk R, Zhang L, Akdis CA. <i>International consensus on allergy immunotherapy</i>. J Allergy Clin Immunol. 2015;136(3):556-68 <i>FI: 12,485</i>  <a href="http://www.jacionline.org/article/S0091-6749(15)00775-7/fulltext">http://www.jacionline.org/article/S0091-6749(15)00775-7/fulltext</a></p> <p>17. Garcia-Larsen V, Del Giacco SR, Moreira A, Bonini M, Charles D, Reeves T, Carlsen KH, Haahtela T, Bonini S, Fonseca J, Agache I, Papadopoulos NG, Delgado L. <i>Asthma and dietary intake: an overview of systematic reviews</i>. Allergy 2016; 71(4):433-42. <i>FI: 6,335</i>  <a href="http://onlinelibrary.wiley.com/doi/10.1111/all.12800/full">http://onlinelibrary.wiley.com/doi/10.1111/all.12800/full</a></p> <p>18. Garcia-Larsen V, Del Giacco SR, Moreira A, Bonini M, Haahtela T, Bonini S, Carlsen KH, Agache I, Fonseca J, Papadopoulos NG, Delgado L. <i>Dietary intake and risk of asthma in children and adults: protocol for a systematic review and meta-analysis</i>. Clin Transl Allergy. 2016;6:17  <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848851/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848851/</a></p> <p>19. Harris JM, Maciucia R, Bradley MS, Cabanski CR, Scheerens H, Lim J, Cai F, Kishnani M, Liao XC, Samineni D, Zhu R, Cochran C, Soong W, Diaz JD, Perin P, Tsukayama M, Dimov D, Agache I, Kelsen SG. <i>A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma</i>. Respir Res. 2016; 17:29. <i>FI: 3,751</i></p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p><a href="https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-016-0347-2">https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-016-0347-2</a></p> <p>20. Jutel M, <i>Agache I</i>, Bonini S, Burks AW, Calderon M, Canonica W, Cox L, Demoly P, Frew AJ, O'Hehir R, Kleine-Tebbe J, Muraro A, Lack G, Larenas D, Levin M, Martin BL, Nelson H, Pawankar R, Pfaar O, van Ree R, Sampson H, Sublett JL, Sugita K, Du Toit G, Werfel T, Gerth van Wijk R, Zhang L, Akdis M, Akdis CA. <i>International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics</i>. J Allergy Clin Immunol. 2016; 137(2): 358-68 <i>FI: 12,485</i></p> <p><a href="http://www.jacionline.org/article/S0091-6749(15)03114-0/fulltext">http://www.jacionline.org/article/S0091-6749(15)03114-0/fulltext</a></p> <p>21. Klimek L, Bachert C, Sjarne, P, Dollner, R, Larsen P, Haahr P, <i>Agache I</i>, Scadding G, Price D - <i>MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: A pan-European study</i>, Allergy Asthma Proc. 2016;37(5):376-86, <i>FI: 2,709</i></p> <p><a href="https://www.ncbi.nlm.nih.gov/pubmed/27657521">https://www.ncbi.nlm.nih.gov/pubmed/27657521</a></p> <p>22. Matricardi PM, Kleine-Tebbe J, Hoffmann HJ, Valenta R, Hilger C, Hofmaier S, Aalberse RC, <i>Agache I</i>, et al. <i>EAACI Molecular Allergology User's Guide</i>. Pediatr Allergy Immunol. 2016;27 Suppl 23:1-250 <i>FI: 3,947</i></p> <p><a href="http://onlinelibrary.wiley.com/doi/10.1111/pai.12563/full">http://onlinelibrary.wiley.com/doi/10.1111/pai.12563/full</a></p> <p>23. Bousquet J, Bewick M, Cano A, Eklund P, Fico G, Goswami N, Guldemond NA, Henderson D, Hinkema MJ, Liotta G, Mair A, Molloy W, Monaco A, Monsonis-Paya I, Nizinska A, Papadopoulos H, Pavlickova A, Pecorelli S, Prados-Torres A, Roller-Wirnsberger RE, Somekh D, Vera-Muñoz C, Visser F, Farrell J, Malva J, Andersen Ranberg K, Camuzat T, Carriazo AM, Crooks G, Gutter Z, Iaccarino G, Manuel de Keenoy E, Moda G, Rodriguez-Mañas L, Vontetsianos T, Abreu C, Alonso J, Alonso-Bouzon C, Ankri J, Arredondo MT, Avolio F, Bedbrook A, Białoszewski AZ, Blain H, Bourret R, Cabrera-Umpierrez MF, Catala A, O'Caomh</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>R, Cesari M, Chavannes NH, Correia-da-Sousa J, Dedeu T, Ferrando M, Ferri M, Fokkens WJ, Garcia-Lizana F, Guérin O, Hellings PW, Haahtela T, Illario M, Inzerilli MC, Lodrup Carlsen KC, Kardas P, Keil T, Maggio M, Mendez-Zorrilla A, Menditto E, Mercier J, Michel JP, Murray R, Noguez M, O'Byrne-Maguire I, Pappa D, Parent AS, Pastorino M, Robalo-Cordeiro C, Samolinski B, Siciliano P, Teixeira AM, Tsartara SI, Valiulis A, Vandenplas O, Vasankari T, Vellas B, Vollenbroek-Hutten M, Wickman M, Yorgancioglu A, Zuberbier T, Barbagallo M, Canonica GW, Klimek L, Maggi S, Aberer W, Akdis C, Adcock IM, <i>Agache I</i>, et al. <i>Building Bridges for Innovation in Ageing: Synergies between Action Groups of the EIP on AHA</i>. J Nutr Health Aging. 2017;21(1):92-104. <i>FI: 3,199</i>  <a href="http://link.springer.com/article/10.1007/s12603-016-0803-1">http://link.springer.com/article/10.1007/s12603-016-0803-1</a></p> <p>24. <i>Agache I</i>, Deleanu D, Khaltaev N, Bousquet J. <i>Allergic rhinitis and its impact upon asthma-update (ARIA 2008). Romanian perspective</i>. Pneumologia. 2009;58(4):255-8</p> <p>25. <i>Agache I</i>, Ciobanu C, Paul G, Rogozea L. <i>Dysfunctional breathing phenotype in adults with asthma - incidence and risk factors</i>. Clin Transl Allergy. 2012;2(1):18.</p> <p>26. <i>Agache IO</i>, Rogozea L. <i>Management of hypersensitivity pneumonitis</i>. Clin Transl Allergy. 2013 Feb 4;3(1):5.  <a href="http://ctajournal.biomedcentral.com/articles/10.1186/2045-7022-3-5">http://ctajournal.biomedcentral.com/articles/10.1186/2045-7022-3-5</a></p> <p>27. Lukat K, Rivas P, Roger A, Kowalski M, Botzen U, Wessel F, Sanquer F, <i>Agache I</i>, Izquierdo I. <i>A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhinoconjunctivitis: a randomized, double-blind, placebo-controlled study</i>. J Asthma Allergy. 2013; 6:31-9.</p> <p>28. Papadopoulos NG, <i>Agache I</i>, Bavbek S, Bilo BM, Braido F, Cardona V, et al. <i>Research needs in allergy: an EAACI position paper, in collaboration with EFA</i>. Clin Transl Allergy. 2012;2(1):21.</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>29. <i>Agache IO. Endotype Driven Treatment of Asthma. Curr Treat Options Allergy 2014; 1: 198</i></p> <p>30. <i>Agache I. Non-eosinophilic Asthma Endotypes. Curr Treat Options Allergy 2015; 2: 257</i></p> <p>31. Bousquet J, Hellings PW, Agache I, Bedbrook A, et al. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy. 2016 Dec 30;6:47.</p> <p>32. Garcia-Larsen V, Del Giacco SR, Moreira A, Bonini M, Haahtela T, Bonini S, Carlsen KH, Agache I, Fonseca J, Papadopoulos NG, Delgado L. Dietary intake and risk of asthma in children and adults: protocol for a systematic review and meta-analysis. Clin Transl Allergy. 2016 Apr 28; 6: 17.</p> <p>33. Dhami S, Nurmatov U, Agache I, et al. Allergen immunotherapy for allergic asthma: protocol for a systematic review. Clin Transl Allergy. 2016 Feb 9; 6:5.</p>
		<p><b>2.3 granturi /proiecte câștigate prin competiție (director /responsabil proiect)</b></p>	<p><b>Criterii obligatorii:</b>            Profesor – minim 3 granturi/proiecte, din care 1 ca director de proiect</p> <p><b>Îndeplinire:</b>            - director de proiect: 1            -membru în 6 proiecte de cercetare            - 50 studii clinice</p>		<p><b>Director de proiect</b>            a. 2015-2017, Endotipurile astmului non-eozinofilic la adult, PN-II-RU-TE-2014-4-2303</p> <p><b>Membru în proiect</b>            1. 2014-2017, COST Action BM 1201, Developmental origins of chronic lung disease, STSM Coordinator and member in the WG Infant Lung Development            2. 2015-2020, Integrated care pathways for airway diseases (AIRWAYS-ICPs), Working Package 10 of the European Innovation Partnership on Active and Healthy Ageing, Action Plan B3; Mechanisms of the Development of Allergy            3. 2007, Programul IMPACT, Proiect CERICARD 908/13 iunie 2007 - Laborator</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>de cercetare și management integrat în insuficiența cardiacă - admis pentru finanțare - 10472375 lei, Coordonator proiect Prof. Dr. Mariana Rădoi; Funcție în proiect - Responsabil echipamente și programe de cercetare fundamentală în insuficiența cardiacă</p> <p>4. 2007 - 2010, Contract de cercetare PN2-ID-146/2007 - Modele de testarea condițiilor de admisibilitate a proceselor și produselor din industria lemnului pe piețele europene, cu impact direct asupra calității mediului, în contextul dezvoltării durabile; valoare 784 705 lei. Coordonator proiect Prof. Dr. Loredana Anne-Marie Bădescu, Membru în echipa de cercetare</p> <p>5. 2004-2007, Proiect CNCISIS contract nr. 1339/2004, Rețea de excelență științifică pentru Industria Lemnului din România în contextul integrării țării noastre în Uniunea Europeană în 2007, valoare 136.000 lei, Conducător de proiect Prof. Dr. Ing. Loredana Anne-Marie Bădescu, Membru în echipa de cercetare</p> <p>6. 2000-2003, Proiect CNCISIS contract 3993/14.06.2000 “Infecția cu Chlamydia Pneumoniae ca factor de risc în sindroame coronariene acute, stroke și ocluzia arterelor periferice“, valoare 100 000 lei, Coordonator proiect Prof. Dr. Mariana Rădoi, Membru în echipa de cercetare</p> <p><b>Studii de cercetare clinică</b></p> <p>1. 2017, Investigator Principal - A Phase III, 24 week, randomized, double-blind, parallel group study, comparing the efficacy, safety and tolerability of the fixed dose combination FF/UMEC/VI with the fixed dose dual combination of FF/VI, administered once-daily via a dry powder inhaler in subjects with inadequately controlled asthma, sponsor GSK</p> <p>2. 2016, Investigator Principal - a phase IIB, randomized, double-blind, placebo-controlled, multicenter, dose-ranging study to assess the efficacy and safety of</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>MSTT1041a in patients with uncontrolled severe asthma, sponsor Genentech</p> <p>3. 2016, Investigator Principal - Studiu randomizat, multicentru, dublu-orb, placebo controlat, cu durata de 52 de săptămâni pentru a evalua eficacitatea și siguranța QAW039 adăugat terapiei existente anti-astmatice la pacienții cu astm sever necontrolat, sponsor Novartis</p> <p>4. 2016, Investigator Principal - Studiu multicentric, randomizat, cu durata de 52 de săptămâni, în regim dublu orb, cu triplă mascare a formei farmaceutice, pe grupe paralele pentru compararea eficacității și a siguranței medicamentului QMF149 cu cele ale furoatului de mometazonă la pacienții cu astm, sponsor Novartis</p> <p>5. 2015, Investigator Principal - Study of Reslizumab in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils, Sponsor Teva Branded Pharmaceutical Products, R&amp;D Inc.</p> <p>6. 2015, Investigator Principal - A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection (SPIRITUS), Sponsor Biota Pharmaceuticals, Inc.</p> <p>7. 2014, Investigator Principal - A Clinical Study Comparing Symbicort 'as Needed' With Pulmicort Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma, sponsor AstraZeneca</p> <p>8. 2014, Investigator Principal - An Open-label, Multi-center, Extension Study to Evaluate the Long-term Safety of Subcutaneous 240mg QGE031 Given Every 4 Weeks for 52 Weeks in Allergic Asthma Patients Who Completed Study CQGE031B2201, sponsor Novartis</p> <p>9. 2014, Investigator Principal - A Randomized, Double-blind, Double-dummy, Parallel Group, Multicenter Study of Once Daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, Twice Daily Fluticasone Propionate/Salmeterol</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>250/50 mcg Inhalation Powder, and Twice Daily Fluticasone Propionate 250 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents Already Adequately Controlled on Twice-daily Inhaled Corticosteroid and Long-acting beta2 Agonist, Sponsor GlaxoSmithKline</p> <p>10. 2014, Investigator Principal – A Clinical Study Comparing Symbicort® 'as Needed' With Terbutaline 'as Needed' and With Pulmicort® Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma, Sponsor – AstraZeneca</p> <p>11. 2014, Investigator Principal – A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting <math>\beta</math>2-agonists, Sponsor Novartis Pharmaceuticals</p> <p>12. 2013, Investigator Principal – A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting <math>\beta</math>2 Agonist (CALIMA), Sponsor – AstraZeneca</p> <p>13. 2013, Investigator Principal – A 6-month, Randomised, Double-blind, Placebo-controlled, Multi-centre, Parallel-group, Phase II Study With an Optional Safety Extension Treatment Period up to 6 Months, to Evaluate the Efficacy, Safety, and Tolerability of 3 Different Doses of AZD5069 Twice Daily as Add-on Treatment to Medium to High Dose Inhaled Corticosteroids (ICS) and Long-acting <math>\beta</math>2 Agonists (LABA), in Patients With Uncontrolled Persistent Asthma), Sponsor – AstraZeneca</p> <p>14. 2013, Investigator Principal – A Double-blind, Placebo-controlled,</p>



**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients, Sponsor – AstraZeneca</p> <p>15. 2013, Investigator Principal – A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults With Persistent Asthma (Protocol No. P06241 Also Known as P202), Sponsor - Merck Sharp &amp; Dohme Corp.</p> <p>16. 2012, Investigator Principal – A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily Compared With Placebo in Adolescent and Adult Subjects With Severe Persistent Asthma Uncontrolled on High Dose Inhaled Corticosteroid Therapy, Sponsor Teva Pharmaceutical Industries</p> <p>17. 2012, Investigator Principal – A 52-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Roflumilast 500 µg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS), Sponsor Forest Laboratories</p> <p>18. 2012, Investigator Principal – A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone Propionate Inhalation Powder 100mcg Twice Daily and Montelukast 10mg Once Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma while Treated</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>with Short Acting Beta2-agonist, Sponsor GSK</p> <p>19. 2012, Investigator Principal – A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma, Sponsor Boehringer Ingelheim</p> <p>20. 2012, Investigator Principal - A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet (MT-06), Sponsor ALK-Abelló A/S</p> <p>21. 2012, Investigator Principal – A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA), Sponsor – Genentech</p> <p>22. 2012, Investigator Principal – phase III, 8-week, multinational, multicentre, randomized, double-blind, triple-dummy, active controlled, 3-arm parallel-group clinical trial to test the efficacy of CHF 1535 (fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg) via NEXT DPI® 1 inhalation bid versus same dose of CHF 1535 pMDI and marketed beclomethasone DPI 100 µg 1 inhalation bid on Peak Expiratory Flow in adult asthmatic patients after one month of treatment with marketed fixed dose combination of FOSTER® 1 inhalation bid, Sponsor - Chiesi Farmaceutici S.p.A</p> <p>23. 2012, Investigator Principal – A 12-week, multinational, multicentre, randomised, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of chf 1535 200/6µg (fixed combination beclomethasone dipropionate / formoterol) versus beclomethasone dipropionate in adults asthmatic patients not adequately controlled on high doses of inhaled</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>corticosteroids or on medium dose of inhaled corticosteroids plus long-acting <math>\beta</math>2-agonists, Sponsor - Chiesi Farmaceutici S.p.A</p> <p>24. 2012, Investigator, A 52 week Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 125mcg once-daily alone and in combination with GW642444 25mcg once-daily via novel Dry Powder Inhaler (nDPI) in Subjects with Chronic Obstructive Pulmonary Disease, Sponsor GSK</p> <p>25. 2012, Investigator Principal – A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticasone Furoate 100 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents, Sponsor GSK</p> <p>26. 2011, Investigator - A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared with Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD), Sponsor –GSK</p> <p>27. 2011, Investigator - A 48-week, double blind, randomized, multinational, multicentre, 2-arm parallel group, reference treatment controlled clinical trial of “fixed combination” beclomethasone dipropionate plus formoterol fumarate administered via pmdi (chf 1535 foster®) versus formoterol in patients with severe chronic obstructive pulmonary disease, Sponsor - Chiesi Farmaceutici S.p.A</p> <p>28. 2010, Investigator Principal – A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 and 5 <math>\mu</math>g once daily) compared with placebo and salmeterol HFA MDI (50 <math>\mu</math>g twice daily) over 24</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>weeks in patients with moderate persistent asthma, Sponsor - Boehringer Ingelheim RCV GmbH &amp; Co KG</p> <p>29. 2009, Investigator Principal – Double-blind, placebo-controlled dose-finding study with CYT003-QbG10 in adult patients with rhinoconjunctivitis due to house dust mite allergy, Sponsor: Cytos Biotechnology</p> <p>30. 2008, Investigator Principal - A 12-week, multinational, randomised, double blind, double dummy, 4-arm parallel-group study comparing the efficacy and safety of CHF 1535 (fixed combination of beclomethasone dipropionate + formoterol fumarate) 100 + 6 µg/actuation inhalation powder, administered via the NEXT inhaler, versus CHF 1535 (fixed combination of beclomethasone dipropionate + formoterol fumarate) 100 + 6 µg/actuation, via HFA pressurised inhalation solution, in moderate to severe symptomatic asthmatic patients aged ≥ 12 years under treatment with inhaled corticosteroids, Sponsor: Chiesi Farmaceutici S.p.A</p> <p>31. 2008, Investigator Principal - Efficacy and safety study of the antihistamine V0114CP 2.5mg in the treatment of Perennial allergic rhinites. Randomised, double-blind, three arm parallel group study including placebo and active control arm (levocetirizine 5mg), Sponsor: Institut de Recherche Pierre Fabre</p> <p>32. 2008, Investigator Principal - A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™ 250/10 µg twice daily) in a Single Inhaler (SkyePharma HFA pMDI) with the Administration of Fluticasone (250 µg twice daily) Alone in SkyePharma HFA pMDI and Flovent® HFA pMDI in Adolescent and Adult Patients with Moderate to Severe Asthma, Sponsor: Kos Life Sciences LLC</p> <p>33. 2008, co-investigator - A randomised, 4-week, placebo-controlled, double-</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>blind, 6 arm parallel group, dose-finding clinical trial, to assess the efficacy, safety and pharmacokinetics of three different doses of formoterol (6, 12 &amp; 18μg) combined with the inhaled anticholinergic aclidinium bromide 200μg, aclidinium bromide 200μg monotherapy and formoterol 12μg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe Chronic Obstructive Pulmonary Disease, Sponsor: Laboratorios ALMIRALL, S.A</p> <p>34. 2007, Investigator Principal – Protocol SKY2028-3-004: A randomized, double-blind, placebo-controlled, parallel group, stratified, multi-center, 12-week study comparing the safety and efficacy of fluticasone and formoterol combination (FlutiForm 100/10 μg or 250-10 μg twice daily) in a single inhaler (SkyePharma hfa pmdi) with the administration of placebo or fluticasone (250 μg twice daily) and formoterol (10 μg twice daily) alone in adolescent and adult patients with moderate to severe asthma, Sponsor: SkyePharma AG.</p> <p>35. 2007, Investigator Principal – A randomised double-blind placebo-controlled study to assess the safety of oral microencapsulated ragweed pollen extract administered for one-year, Sponsor: Curalogic A/S</p> <p>36. 2007, Investigator Principal – A study of the efficacy, safety, and quality of life (QoL) in patients with chronic idiopathic urticaria dosed with AERIUS tablets (5 mg, 10 mg, or 20 mg once daily), Sponsor: Schering-Plough</p> <p>37. 2007, Investigator Principal – Open-label, blinded endpoint, randomized, parallel treatment study to compare the clinical efficacy of PURETHAL Bee and Alutard SQ Bee, Sponsor Hal Allergy BV</p> <p>38. 2006, Investigator Principal – Protocol MK0476-332: A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>Placebo in Patients With Chronic Asthma Who Smoke Cigarettes, Sponsor: Merck</p> <p>39. 2006, Coinvestigator – A phase III, randomized, parallel study to compare the therapeutic efficacy of SMB BUDESONIDE-SALMETEROL DPI capsule 300/25 µg BID delivered by the Axahaler versus SERETIDE DISKUS 500/50 µg (Fluticasone propionate 500 µg/Salmeterol 50 µg) BID over 12 weeks and evaluate the safety of SMB BUDESONIDE-SALMETEROL 300/25 µg over an additional period of 12 weeks, Sponsor: Remedium Oy</p> <p>40. 2005, Investigator Principal – Protocol RA/PR/033009/004/04: Evaluation of the 24-hour through FEV1 following 7 days of dosing with CHF 4226 2m once daily. A multicenter, double-blind, double-dummy, randomized, parallel group, placebo and active (Formoterol 12 mg bid) controlled study followed by a 3-week open label extension (to either CHF 4226 2mg od or Formoterol 12 mg bid in a 2:1 ratio) for the evaluation of safety and tolerability, Sponsor: Chiesi SA</p> <p>41. 2005, Investigator Principal – Protocol D5899C00001: 12-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy and Safety Study of Symbicort® pMDI 2 x 160/4.5 µg Bid and 2 x 80/4.5 µg Bid Compared to Formoterol Turbuhaler® 2 x 4.5 µg Bid and Placebo in Patients With COPD, Sponsor: AstraZeneca</p> <p>42. 2004, Investigator Principal – Protocol IC05RUP/4/03: A 12-week, multicenter, double-blind, randomised, placebo and active treatment controlled, parallel-group trial to assess the efficacy and safety of rupatadine in the treatment of Seasonal Allergic rhino-conjunctivitis (SAR), Sponsor: J Uriach y Cia SA</p> <p>43. 2004, Investigator Principal – Protocol IC06RUP/3/04: A 12-week, multicenter, double-blind, randomised, placebo and Cetirizine 10 mg controlled study to</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>assess the efficacy and safety of rupatadine 10 mg in the treatment of perennial allergic rhinitis (PAR), Sponsor: J Uriach y Cia SA</p> <p>44. 2004, Investigator Principal – Protocol BILA 1704/RAE: Double-Blind, Randomised, Placebo-Controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Cetirizine 10 mg for the Treatment of Seasonal Allergic Rhinitis, Sponsor: Faes Pharma SA</p> <p>45. 2003, Co-investigator – Protocol D3562C00098: Controlled Rosuvastatin Multinational Study in Heart Failure CORONA A Randomized, Double-Blind, Placebo Controlled Phase III Study With Rosuvastatin in Subjects With Chronic Symptomatic Systolic Heart Failure, Sponsor: AstraZeneca</p> <p>46. 2003, Investigator Principal – Protocol: SD-039-0734, Efficacy of Symbicort® Turbuhaler® 160/4.5 mcg as needed versus Oxis® 4.5 mcg as needed and Bricanyl® 0.4 mg as needed in adults and adolescents with asthma receiving Symbicort® Turbuhaler® 160/4.5 mcg twice daily as maintenance treatment. A 12-month, randomised, double-blind, parallel-group, active-controlled, phase IIIB, multi-centre study, Sponsor: AstraZeneca</p> <p>47. 2003, Investigator principal – Protocol: SD-NEE-0003 A randomized, double-blind, parallel-group multicentre efficacy and safety phase IIB pilot study of esomeprazole 40 mg twice daily versus placebo twice daily in adult asthmatics treated for 4 months, Sponsor: AstraZeneca</p> <p>48. 2003, Co-Investigator – Protocol SCO 100470: A multicentre, randomised, double-blind, parallel group, 24-week study to compare the effect of the salmeterol/fluticasone propionate combination product 50/250mcg, with salmeterol 50mcg both delivered twice daily via the DISKUS/ACCUHALER inhaler on lung function and dyspnoea in subjects with Chronic Obstructive Pulmonary Disease (COPD).</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					49. 2003, Investigator – Protocol SAS30040: A 12-week, randomised, double-blind, parallel-group study to compare the efficacy and tolerability of salmeterol/fluticasone propionate combination 50/100mcg bd with fluticasone propionate 250mcg bd, all via the DISKUS™/ACCUHALER™ on maintaining asthma control in moderate persistent asthmatic subjects whose symptoms have been well-controlled following an initial maintenance therapy with salmeterol/fluticasone propionate 50/250mcg combination twice-daily for 12 weeks, Sponsor: GlaxoSmithKline
					50. 2000, Co-investigator – Protocol SCO30003: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Investigate the Effects of Salmeterol/Fluticasone 50/500mcg Bd, Salmeterol 50mcg Bd, and Fluticasone 500mcg Bd, All Delivered Via the DISKUS/ACCUHALER Inhaler, on the Survival of Subjects With Chronic Obstructive Pulmonary Disease Over 3 Years of Treatment, Sponsor: GlaxoSmithKline
	2.4	articole publicate in reviste si volumele unor manifestări științifice cu ISBN sau ISSN	<b>Criterii obligatorii:</b> Profesor – minim 8 articole din care 3 in ultimii 5 ani		
			<b>Îndeplinire:</b> 18 de articole, dintre care 11 în ultimii 5 ani		1. <a href="#">Agache I</a> ; Duca L; Pamfil G; Anghel M - <i>Antinuclear antibodies in asthma are correlated with lack of asthma control</i> , Journal of allergy and clinical immunology, 2008, 121(2), Supplement: 1, S77-S77, Meeting Abstract: 298 2. Duca L.; Agache I; Anghel M. <i>Risk factors for severe chronic itching in patients with rheumatoid arthritis</i> , Allergy, 2008, 63, Supplement: 88, 271-271, Meeting Abstract: 713 <i>FI:6,204</i> 3. Balan A; <a href="#">Agache I</a> ; Ciobanu C; Anghel M - <i>Predictors of response to hydroxychloroquine in chronic urticarial</i> , Allergy, 2009, 64, 516-516, Meeting Abstract: 1351, <i>FI:6,380</i> 4. Ciobanu C., <a href="#">Agache I</a> <i>Asthma Risk Factors and Phenotypes in Children and in</i>



**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p><i>Adults with Seasonal Allergic Rhinitis</i>, Journal of Allergy and Clinical Immunology, 2010, 125(2), Supplement: S, AB2-AB2 <i>FI:9,273</i></p> <p>5. Ciobanu C., Paul G.; <i>Agache I</i> - <i>Risk factors for difficult asthma in school children according to their clinical phenotypes</i>, Allergy, 2010, 65, Special Issue: SI, Supplement: 92, 674-674, Meeting Abstract: 1839, <i>FI: 6,297</i></p> <p>6. Ciobanu C, <i>Agache I.</i>, Paul G, Barbieru V., Creitaru D., <i>Dysfunctional breathing phenotype in adults with asthma</i>, Allergy, 2011, 66, Special Issue, Supplement: 94, 516-516, Meeting Abstract: 1360 <i>FI: 6,271</i></p> <p>7. Agache, I. O.; Ciobanu, C. <i>Persistent High FeNO Phenotype in Asthma</i>, Journal of Allergy and Clinical Immunology, 2011, 127(2), Supplement: S, AB4-AB4 <i>FI:11,003</i></p> <p>8. Agache I.; Ciobanu C.; Barbieru V. <i>Phenotypes of Rhinitis and Difficult Asthma</i>, Journal of Allergy and Clinical Immunology, 2012, 129(2), Supplement: S, AB10-AB10 <i>FI: 12,047</i></p> <p>9. Rivas P, Kowalski M, Lukat K, Botzen U, Wessel F, Sanquer F, del Cuvillo A, Izquierdo I, <i>Agache I</i> - <i>Rupatadine and desloratadine showed similar profile for seasonal allergic rhinoconjunctivitis</i>, Allergy, 2012, 67, Special Issue, Supplement: 96, 19-19, Meeting Abstract: 40 <i>FI: 5,883</i></p> <p>10. Agache C., Rueckert B., <i>Agache I.</i> et al. <i>Dialysis plus ultrafiltration significantly improves the detection of cytokines in induced sputum</i>, European Respiratory Journal. 42(57), Meeting Abstract: 1436 <i>FI: 7,125</i></p> <p>11. <i>Agache I.</i>, Ciobanu C., Agache C. et al. <i>Induced sputum cytokines and chemokines and mechanistic pathways in adult asthma phenotypes</i>, European Respiratory Journal, 42(57), Meeting Abstract: 1134 <i>FI: 7,125</i></p> <p>12. <i>Agache IO</i>, Ciobanu C, Barbieru V, Rogozea L, <i>Longitudinal Evaluation of the Prognostic Value for Difficult Asthma of Rhinitis Clusters</i>, Journal of Allergy</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>and Clinical Immunology, 2013, 131(2), Supplement: S, AB206-AB206 <i>FI: 11,248</i></p> <p>13. Ciobanu CM, <a href="#">Agache I.</a>, <i>Allergen specific immunotherapy and asthma control and future risk</i>, Allergy. 68(Special Issue, Supplement: 97). 554-554. Published: SEP 2013, Conference: World Allergy and Asthma Congress of the European-Academy-of-Allergy-and-Clinical-Immunology and World-Allergy-Organization <i>FI: 5,995</i></p> <p>14. <a href="#">Agache IO</a>, Agache C, Ruckert B, Rogozea L., Ciobanu C, Akdis CA - <i>Sputum Cytokines and Adult Asthma Endotypes</i>, Journal of allergy and clinical immunology, 2014, 133(2), Supplement: S, AB399-AB399, Meeting Abstract: L6, <i>FI: 11,476</i></p> <p>15. Harris JM, Maciucă R, Bradley S, Cabanski C, Scheerens H, Lim J, Cai F, Kishnani-Johnson M, Liao XC, Samineni D, Zhu R, Cochran C, Soong W, Diaz JD, Perin P, Tsukayama M, Dimov D, <a href="#">Agache I</a>, Kelsen SG, <i>Efficacy And Safety Of Quilizumab In Adults With Allergic Asthma Inadequately Controlled On Inhaled Corticosteroids And A Second Controller (costa Study)</i>, American Journal of Respiratory and Critical Care Medicine, 2015, 191, Meeting Abstract: A5168 <i>FI: 13,118</i></p> <p>16. <a href="#">Agache I</a>; Sarafoleanu CC, Leru PM; Bucur I, Doros I-C, Poenaru M - <i>Real-life effectiveness of a new allergic rhinitis therapy (MP-AzeFlu*) in Romania</i>, (Meeting of the European-Academy-of-Allergy-and-Clinical-Immunology) Allergy. 2016, 71, 102, 386-386, <i>FI: 6,335</i></p> <p>17. Stjarme P, Dollner R, Haahr P, <a href="#">Agache I</a>, &amp; Bachert C. <i>Effectiveness of MP-AzeFlu* for the treatment of allergic rhinitis in real-life: according to phenotype, severity and patient age: meta-analysis of data from 5 European countries</i> (Meeting of the European-Academy-of-Allergy-and-Clinical-</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					Immunology), Allergy. 2016, 71, 211-212, <i>FI: 6,335</i> 18. Klimek L, Stjarne P, Dollner R, Haahr P, Agache I, & Bachert C. <i>Effectiveness of MP-AzeFlu* for the treatment of allergic rhinitis in real-life: meta-analysis of data from Germany, Sweden, Norway, Denmark and Romania</i> . Allergy. 2016, 71, 209-210, <i>FI: 6,335</i>
		<b>2.5. proiecte educaționale și de formare continua</b>	<i>Îndeplinire:</i>		Membru în proiect CEEPUS CIII-AT-0042-11-1516, Image Processing, Information Engineering & Interdisciplinary Knowledge Exchange Membru în proiect CEEPUS CIII-SI-0206-08-1415 (Umbrella) Applications of Rapid Manufacturing in Biomedical Fields
<b>3</b>	<b>Recunoașterea și impactul activității</b>	Premii	<i>Îndeplinire:</i>		
		Citări în reviste ISI și BDI - 0,05 pct/citare	<i>Îndeplinire:</i>	<b>Total 2744 citări ISI</b>	<ul style="list-style-type: none"> <li>• 8522 conform Google Scholar</li> <li>• 2744 conform ISI</li> </ul>
		3.3 Prezentări invitate în plenul unor manifestări științifice naționale și internaționale	<i>Îndeplinire:</i>		1. <i>Ioana Agache</i> , Mariana Rădoi; “Infection with Chlamydia Pneumoniae and atherosclerosis – is there a link?”; EAACI Summer School, Rome-Cagliari, 2000 2. <i>Ioana Agache</i> Mariana Rădoi; Immune inflammatory mechanisms in atherosclerosis, 5th Course: Allergy and Immunology Update (AIU), Swiss Society of Allergology and Immunology, 2003 3. <i>Ioana Agache</i> ; Allergologia, immunologia ed internet, Congresso Interannuale della Societa Italiana di Allergologia e Immunologia Clinica, Rapallo, Italia, 2003 4. <i>Ioana Agache</i> ; Severe asthma, 4th Balkan Congress of Allergology and Clinical Immunology, Bucharest 2005. 5. <i>Ioana Agache</i> ; Asthma in the clinic, EAACI/GA2LEN Summer School, Rotterdam 28-31 august 2005

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<ol style="list-style-type: none"> <li>6. <i>Ioana Agache</i>; Severe asthma, EAACI/ GA2LEN International Summer School, Cluj 5-10 septembrie 2007</li> <li>7. <i>Ioana Agache</i>; Asthma phenotypes, EAACI/ GA2LEN International Summer School, Cluj 5-10 septembrie 2007</li> <li>8. <i>Ioana Agache</i>; Asthma management in Eastern Europe, XXVII EAACI Congress, Barcelona, 7-11 iunie 2008</li> <li>9. <i>Ioana Agache</i>; Daily versus as needed inhaled corticosteroids in children with asthma, EAACI &amp; GA2LEN Allergy Summer School On Paediatric Asthma, Venetia, 4-6 iulie 2008</li> <li>10. <i>Ioana Agache</i>; Asthma in developing world of Eastern Europe, XIX World Congress of Asthma, Monte Carlo, 5-8 Noiembrie 2008</li> <li>11. <i>Ioana Agache</i>; Is anti-microbial therapy an option treat asthma/allergy, XIX World Congress of Asthma, Monte Carlo, 5-8 Noiembrie 2008</li> <li>12. <i>Ioana Agache</i>; Molecular markers of asthma phenotypes and endotypes – December 2011, World Allergy Congress</li> <li>13. <i>Ioana Agache</i>; Chronic cough – is it asthma or something else? – Pediatric Allergy and Asthma Meeting, October, 2011</li> <li>14. <i>Ioana Agache</i>; Immune pathogenesis of asthma exacerbations – June 2011, EAACI Annual Meeting</li> <li>15. <i>Ioana Agache</i>; Daily versus as needed inhaled corticosteroids in children with mild persistent asthma – May 2011, World Congress of Asthma</li> <li>16. <i>Ioana Agache</i>; Allergy management in primary care in Europe – current status - June 2012, EAACI Annual Meeting</li> <li>17. <i>Ioana Agache</i>; Mechanism-guided treatment for asthma – June 2013, EAACI Annual Meeting and World Allergy Congress</li> <li>18. <i>Ioana Agache</i>; Naso-bronchial interaction – March 2013, SERIN meeting</li> </ol>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>19. <i>Ioana Agache</i>; New tools in asthma: biomarkers – June 2014, EAACI Annual Meeting</p> <p>20. <i>Ioana Agache</i>; Lessons from the lower airways – June 2014, European Rhinology Society Annual Meeting</p> <p>21. <i>Ioana Agache</i>; Type 2 asthma endotype – October 2015, World Allergy Congress</p> <p>22. <i>Ioana Agache</i>; The asthma epidemic: How did we come to worldwide 300 Million patients? – October 2015, Global Risk Forum</p> <p>23. <i>Ioana Agache</i>; Asthma phenotypes and endotypes – implications for AIT – October 2015, Polish Allergy Society Annual meeting</p> <p>24. <i>Ioana Agache</i>; Managing anaphylaxis in community settings – June 2015, EAACI Annual Meeting</p> <p>25. <i>Ioana Agache</i>; EAACI Food Allergy and Anaphylaxis Guidelines – March 2015, SLAAAI Congress</p> <p>26. <i>Ioana Agache</i>; Precision medicine in asthma – November 2016, European Rhinology Forum</p> <p>27. <i>Ioana Agache</i>; Precision medicine in allergy and asthma - October 2016, Joint Congress of APAAACI &amp; APAPARI 2016</p> <p>28. <i>Ioana Agache</i>; Appraising the Evidence: Is Precision Medicine Ready for the Clinic? – October 2016, 9th Hong Kong Allergy Convention</p> <p>29. <i>Ioana Agache</i>; The Complexity of Type 2 Asthma Endotype - October 2016, 9th Hong Kong Allergy Convention</p> <p>30. <i>Ioana Agache</i>; Serum IL-5 and IL-13 consistently serve as the best predictors for the blood eosinophilia phenotype in adult asthmatics – September 2016, European Respiratory Society Annual Meeting</p> <p>31. <i>Ioana Agache</i>; Food allergy and asthma – September 2016, XLIII Congresso</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>Brasileiro de Alergia e Imunologia</p> <p>32. <i>Ioana Agache</i>; Use of biomarkers in personalized medicine – June 2016, EAACI Annual Congress</p> <p>33. <i>Ioana Agache</i>; Can we afford a system change to prevent disease progression? – January 2016, Allergy Think Tank</p> <p>34. <i>Ioana Agache</i>; Microbiome and Asthma: An Obvious but Often Overlooked Parameter – March 2017, AAAAI Annual Meeting</p> <p>35. <i>Ioana Agache</i>; Non eosinophilic asthma endotypes – March 2017, XIV International Congress „Current problems of immunology, allergology and immunopharmacology”</p> <p>36. <i>Ioana Agache</i>; Phenotypes and endotypes in allergy – November 2017, 7th International Symposium on Molecular Allergology</p>
		3.4.profesor invitat (exclusive ERASMUS)	<i>Îndeplinire:</i>		
		3.5. membru în colectivele de redacție sau comitete științifice, organizator de manifestări științifice	<i>Îndeplinire:</i>	<b>Membru în comitetul de organizare:</b>	<ul style="list-style-type: none"> <li>• Simpozionul PAPRICA in colaborare cu EAACI – Brasov, 8 Octombrie 2011</li> <li>• Congresul Internațional de Astmologie (World Congress of Asthma), Monte Carlo, 5-8 Noiembrie 2008</li> <li>• Scoala de vara cu tema “Paediatric asthma” organizata de Academia Europeana de Alergologie si Imunologie Clinica la Venetia, 4-6 iulie 2008</li> <li>• Școala de vara “Asthma and allergy: bridging the gap between basic and clinical science ” organizata de Academia Europeana de Alergologie si Imunologie Clinica la Rotterdam, 28-31 august 2005</li> <li>• 4<sup>th</sup> Balkan Congress of Allergology &amp; Clinical Immunology, București, 22-25 Septembrie 2005</li> </ul>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<ul style="list-style-type: none"> <li>• Conferința Națională Anuală a Societății Române de Alergologie și Imunologie Clinică cu participare internațională, Brașov, 07-09 Octombrie 2004</li> <li><b>Membru în comitetul științific</b></li> <li>• al XXVII EAACI Congress: Clinical Features of Allergy: From Pediatric to Geriatric, Barcelona, 7-11 iunie 2008</li> <li>• al XXVI EAACI Congress, Goteborg, 9-13 iunie 2007</li> <li>• al XXV EAACI Congress, Viena, 10-14 iunie 2006</li> <li>• Interasthma – EAACI Joint Meeting, Bilbao, 28 noiembrie 2004</li> <li>• Conferința Anuală de Alergologie și Imunologie Clinică, București Octombrie 2009</li> <li>• Conferința Anuală de Alergologie și Imunologie Clinică, Baia Mare 1-4 Mai 2008</li> <li>• Congresul Societății Române de Alergologie și Imunologie Clinică cu participare internațională, Târgu Mureș, 26-28 Aprilie 2007</li> <li>• Conferința Națională Anuală a Societății Române de Alergologie și Imunologie Clinică cu participare internațională, Brașov, 07-09 Octombrie 2004</li> <li><b>Chairperson</b></li> <li>• XXVII EAACI Congress, Barcelona, 7-11 iunie 2008: Symposium - Relationship Between Objective and Subjective Outcome Measures in Airway Disease, Symposium - Pro &amp; Con: Mild Persistent Asthma Does Require Regular Treatment, Poster session - Risk Factors and Triggers of Asthma</li> <li>• EAACI &amp; GA2LEN Allergy Summer School on Pediatric Asthma 2008, Venetia 5-8 iulie 2008: Phenotypes of childhood asthma</li> <li>• ERS Congress, Berlin 4-8 octombrie 2008: Understanding allergic airway inflammation with the help of animal model</li> <li>• World Allergy Congress, Bangkok 2-7 Decembrie 2007: Sister Society Symposium - Interasma Congress 08 Montecarlo - Difficult to Control Asthma</li> <li>• Al XXVI EAACI Congress, Goteborg, 9-13 iunie 2007: Symposium - Severe</li> </ul>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>and Difficult to Treat Asthma, Poster session – Asthma and Allergy, Poster session – From Immnodeficiency to Autoimmunity</p> <ul style="list-style-type: none"> <li>• Al XXV EAACI Congress, Viena, 10-14 iunie 2006: Poster session – Clinical and Occupational Asthma</li> <li>• GA<sup>2</sup>LEN/EAACI Summer School Rotterdam 2005: How should we assess and monitor asthma?</li> <li>• Interasthma – EAACI Joint Meeting, Bilbao, 28 noiembrie 2004: Plenary Session Asthma in the world</li> <li>• Al XXIII EAACI Congress, Amsterdam 12-16 iunie 2004: JMA Poster Session</li> <li>• EAACI- Section ENT Meeting, Gent, Belgium, 15-18 November 2003: Plenary Session - Future treatments of nasal disease</li> <li>• Conferinței Naționale Anuale a Societății Române de Alergologie și Imunologie Clinică cu participare internațională, Brașov, 07-09 Octombrie 2004</li> </ul>
		3.6 recenzor pentru reviste și manifestări științifice naționale și internaționale indexate ISI/BDI	<i>Îndeplinire:</i>		<ul style="list-style-type: none"> <li>• 2010 – prezent – Editor Asociat, Clinical and Translational Allergy</li> <li>• 2015-prezent – Membru in comitetul de redactie al Polish Journal of Allergology</li> <li>• 2009-2013, Editor Newsletter EAACI</li> <li>• 2005-2007, Redactor șef adjunct la revista Societății Române de Alergologie și Imunologie Clinică</li> <li>• 2007-2008, Membru in colegiu de redacție la revista Societății Române de Alergologie și Imunologie Clinică</li> </ul>
		3.7 membru comisii de doctorat (exclusiv președinte) și			<ul style="list-style-type: none"> <li>•</li> </ul>



**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
		abilitare			
		3.8 experiența de management în cercetare și/sau învățământ	<i>Îndeplinire:</i>	<p>Societati si structuri nationale</p> <p>Societati internationale</p>	<ul style="list-style-type: none"> <li>• 2004-2008, Membru in Consiliu Profesional al Facultății de Medicină, Universitatea Transilvania din Brașov</li> <li>• 2004-2006, Membru in Comitetul Director al Societății Române de Alergologie și Imunologie Clinică</li> <li>• 2005-2006, Membru în Comisia de Alergologie din cadrul comisiilor de specialitate a Ministerul Sănătății Publice</li> <li>•</li> <li>• Presedinte Ales al Academiei Europene de Alergologie si Imunologie Clinica 2017-2019</li> <li>• Vice-Presedinte din 2013-2017 al Academiei Europene de Alergologie si Imunologie Clinica</li> <li>• Membru in Executive Committee al Academiei Europene de Alergologie si Imunologie Clinica 2009-2013</li> <li>• Secretar al Sectiunii de Astm al Academiei Europene de Alergologie si Imunologie Clinica 2005-2009</li> <li>• Membru in ARIA (Allergic Rhinitis and Impact on Asthma) Advisory Committee din 2008</li> <li>• Membru a Scientific Program Committee al Academiei Europene de Alergologie si Imunologie Clinica din 2005</li> <li>• Membru a World Allergy Organisation Asthma Special Committee 2008-2009</li> <li>• Membru a World Allergy Organisation Communication Council 2008-2009</li> <li>• Membru a World Allergy Organisation Allergy Diagnosis Special Committee 2008-2009</li> </ul>
		3.9. participare	<i>Îndeplinire:</i>	Conferinte	1. Elena Bobescu, Mariana Rădoi, <i>Ioana Agache</i> , A. Burducea; “Correlation

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
		efectivă manifestări științifice		internationale	<p>between oxidative stress, inflammatory syndrome and prognosis in patients with acute coronary syndromes”; 11th International Conference on Advances in Prostaglandin and Leukotriene Research: Basic Science and New Clinical Application, Florence, Italy, June 4 –8, 2000</p> <p>2. <i>Ioana Agache</i>, Mariana Rădoi; “Infection with Chlamydia Pneumoniae and atherosclerosis – is there a link?”; EAACI Summer School, Rome-Cagliari, 2000</p> <p>3. Mariana Rădoi, Elena Bobescu, <i>Ioana Agache</i>, Claudia Timu; “Serological status for Chlamydia Pneumoniae, systemic inflammation and one month evolution of patients with unstable angina”; First International Symposium on PPARs: from basic science to clinical applications. Florence, April 4-7, 2001</p> <p>4. Mariana Rădoi, <i>Ioana Agache</i>; "Immune-inflammatory mechanisms in atherosclerosis", Annual Conference of the Romanian Society of Allergology and Clinical Immunology with international participation, Bucharest 2002, vol. rez. pg. 53; 2002</p> <p>5. Mariana Rădoi, Elena Bobescu, <i>Ioana Agache</i>, Florin Leasu; Rovamycine as add-on treatment in unstable angina and 4 year evolution with major cardiovascular events”; 12th International Congress on Cardiovascular Pharmacotherapy; 2003</p> <p>6. <i>Ioana Agache</i>; Efficacy of montelukast and loratadine combination in perennial allergic rhinitis, World Allergy Organisation Congress - XVIII ICACI, Vancouver, 7-12 Septembrie 2003</p> <p>7. Mariana Rădoi, <i>Ioana Agache</i>, Elena Bobescu, Mariana Anghel; Serological status for Chlamydia Pneumoniae in patients with acute coronary syndromes in correlation with IL6 and TGF beta serum levels, 1st International Conference on Cytokine Medicine, Manchester 27-28 februarie 2003</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>8. <i>Ioana Agache</i>; Immune inflammatory mechanisms in atherosclerosis, 5th Course: Allergy and Immunology Update (AIU), Swiss Society of Allergology and Immunology, 2003</p> <p>9. <i>Ioana Agache</i>; Allergologia, immunologia ed internet, Congresso Interannuale della Societa Italiana di Allergologia e Immunologia Clinica, Rapallo, Italia, 2003</p> <p>10. Mariana Rădoi, Elena Bobescu, <i>Ioana Agache</i>, Mariana Anghel, Liliana Eftimie; “Antibodies against ox LDL in correlation with IgG and IgA anti Chlamydia Pneumoniae serum titers in 54 patients with acute coronary syndromes”; First Romanian Symposium with International Participation - Inflammation 2004.</p> <p>11. <i>Ioana Agache</i>, Liliana Eftimie; Significance of increased serum levels of beta 2 microglobulin in patients with antiphospholipid antibodies syndrome – study on 55 cases, 12th International Congress of Immunology and 4th Annual Conference of FOCIS, Montreal, Canada, 2004,</p> <p>12. <i>Ioana Agache</i>; Severe asthma, 4th Balkan Congress of Allergology and Clinical Immunology, Bucharest 2005.</p> <p>13. <i>Ioana Agache</i>; Asthma in the clinic, EAACI/GA2LEN Summer School, Rotterdam 28-31 august 2005</p> <p>14. <i>Ioana Agache</i>; Severe asthma, EAACI/ GA2LEN International Summer School, Cluj 5-10 septembrie 2007</p> <p>15. <i>Ioana Agache</i>; Asthma phenotypes, EAACI/ GA2LEN International Summer School, Cluj 5-10 septembrie 2007</p> <p>16. <i>Ioana Agache</i>; Asthma management in Eastern Europe, XXVII EAACI Congress, Barcelona, 7-11 iunie 2008</p> <p>17. <i>Ioana Agache</i>; Daily versus as needed inhaled corticosteroids in children with</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>asthma, EAACI &amp; GA2LEN Allergy Summer School On Paediatric Asthma, Venetia, 4-6 iulie 2008</p> <p>18. <i>Ioana Agache</i>; Increased serum IL-17 is an independent risk factor for severe asthma, ERS Congress, Berlin 4-8 octombrie 2008</p> <p>19. <i>Ioana Agache</i>; Asthma in developing world of Eastern Europe, XIX World Congress of Asthma, Monte Carlo, 5-8 Noiembrie 2008</p> <p>20. <i>Ioana Agache</i>; Is anti-microbial therapy an option treat asthma/allergy, XIX World Congress of Asthma, Monte Carlo, 5-8 Noiembrie 2008</p> <p>21. <i>Ioana Agache</i>; Molecular markers of asthma phenotypes and endotypes – December 2011, World Allergy Congress</p> <p>22. <i>Ioana Agache</i>; Chronic cough – is it asthma or something else? – Pediatric Allergy and Asthma Meeting, October, 2011</p> <p>23. <i>Ioana Agache</i>; Immune pathogenesis of asthma exacerbations – June 2011, EAACI Annual Meeting</p> <p>24. <i>Ioana Agache</i>; Daily versus as needed inhaled corticosteroids in children with mild persistent asthma – May 2011, World Congress of Asthma</p> <p>25. <i>Ioana Agache</i>; Allergy management in primary care in Europe – current status - June 2012, EAACI Annual Meeting</p> <p>26. <i>Ioana Agache</i>; Mechanism-guided treatment for asthma – June 2013, EAACI Annual Meeting and World Allergy Congress</p> <p>27. <i>Ioana Agache</i>; Naso-bronchial interaction – March 2013, SERIN meeting</p> <p>28. <i>Ioana Agache</i>; New tools in asthma: biomarkers – June 2014, EAACI Annual Meeting</p> <p>29. <i>Ioana Agache</i>; Lessons from the lower airways – June 2014, European Rhinology Society Annual Meeting</p> <p>30. <i>Ioana Agache</i>; Induced sputum cytokines and chemokines and mechanistic</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>pathways in adult asthma phenotypes – September 2014, European Respiratory Society Annual Meeting</p> <p>31. <i>Ioana Agache</i>; Type 2 asthma endotype – October 2015, World Allergy Congress</p> <p>32. <i>Ioana Agache</i>; The asthma epidemic: How did we come to worldwide 300 Million patients? – October 2015, Global Risk Forum</p> <p>33. <i>Ioana Agache</i>; Asthma phenotypes and endotypes – implications for AIT – October 2015, Polish Allergy Society Annual meeting</p> <p>34. <i>Ioana Agache</i>; Managing anaphylaxis in community settings – June 2015, EAACI Annual Meeting</p> <p>35. <i>Ioana Agache</i>; EAACI Food Allergy and Anaphylaxis Guidelines – March 2015, SLAAAI Congress</p> <p>36. <i>Ioana Agache</i>; Precision medicine in asthma – November 2016, European Rhinology Forum</p> <p>37. <i>Ioana Agache</i>; Precision medicine in allergy and asthma - October 2016, Joint Congress of APAAACI &amp; APAPARI 2016</p> <p>38. <i>Ioana Agache</i>; Appraising the Evidence: Is Precision Medicine Ready for the Clinic? – October 2016, 9th Hong Kong Allergy Convention</p> <p>39. <i>Ioana Agache</i>; The Complexity of Type 2 Asthma Endotype - October 2016, 9th Hong Kong Allergy Convention</p> <p>40. <i>Ioana Agache</i>; Serum IL-5 and IL-13 consistently serve as the best predictors for the blood eosinophilia phenotype in adult asthmatics – September 2016, European Respiratory Society Annual Meeting</p> <p>41. <i>Ioana Agache</i>; Food allergy and asthma – September 2016, XLIII Congresso Brasileiro de Alergia e Imunologia</p> <p>42. <i>Ioana Agache</i>; Use of biomarkers in personalized medicine – June 2016,</p>

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					EAACI Annual Congress 43. <i>Ioana Agache</i> ; Can we afford a system change to prevent disease progression? – January 2016, Allergy Think Tank 44. <i>Ioana Agache</i> ; Microbiome and Asthma: An Obvious but Often Overlooked Parameter – March 2017, AAAAI Annual Meeting 45. <i>Ioana Agache</i> ; Non eosinophilic asthma endotypes – March 2017, XIV International Congress „Current problems of immunology, allergology and immunopharmacology” 46. <i>Ioana Agache</i> ; Phenotypes and endotypes in allergy – November 2017, 7th International Symposium on Molecular Allergology
				Conferinte nationale	1. <i>Ioana Agache</i> ; Calea duală a inflamației în astm, Conferința Națională Anuală a Societății Române de Alergologie și Imunologie Clinică 2004 2. <i>Ioana Agache</i> ; Mecanisme imun-inflamatorii în ateroscleroză, al VII-lea Simpozion Național Prof. Dr. Dimitrie Gerota, 2004 3. <i>Ioana Agache</i> ; Limfocitele T reglatorii, Congresul Național al Societății Române de Alergologie și Imunologie Clinică cu participare internațională, Târgu Mureș 2007 4. <i>Ioana Agache</i> ; Rolul autoimunității în astm, Congresul Național al Societății Române de Alergologie și Imunologie Clinică cu participare internațională, Târgu Mureș 2007 5. <i>Ioana Agache</i> ; Relația rinită-astm: date din viața reală, Congresul Național al Societății Române de Alergologie și Imunologie Clinică cu participare internațională, Târgu Mureș 2007 6. <i>Ioana Agache</i> ; Congestia nazală, Congresul Național al Societății Române de Alergologie și Imunologie Clinică cu participare internațională, Târgu Mureș 2007

**FISA DE VERIFICARE – Ioana Agache**  
**A INDEPLINIRII STANDARDELOR MINIME NATIONALE**  
**in conformitate cu grila de evaluare a comisiei CNATDCU**

MONITORUL OFICIAL AL ROMÂNIEI, PARTEA I, Nr. 890 bis/27.XII.2012

**Anexa nr. 20 - COMISIA MEDICINĂ**

**STANDARDE MINIMALE NECESARE ȘI OBLIGATORII PENTRU CONFERIREA ABILITĂRII**

Nr crt	Activitatea	Tipul activității	Categoriile și restricții	Subcategoriile	Indiatori Kpi
0	1	2	3	4	5
					<p>7. <i>Ioana Agache</i>; Our experience on acquired C1 inhibitor deficiency in autoimmune disorders, Conferința Anuală de Alergologie și Imunologie Clinică, Baia Mare 1-4 Mai 2008</p> <p>8. <i>Ioana Agache</i>; Interventia IL-17 in autoimunitate și inflamatie, Conferința Anuală de Alergologie și Imunologie Clinică, Baia Mare 1-4 Mai 2008</p> <p>9. <i>Ioana Agache</i>; Alegerea unui beta 2 agonist cu durata lunga de actiune conteaza?, Conferința Anuală de Alergologie și Imunologie Clinică, Baia Mare 1-4 Mai 2008</p> <p>10. <i>Ioana Agache</i>; Fenotipurile în astmul bronșic al adultului, Conferința Anuală de Alergologie și Imunologie Clinică, Baia Mare 1-4 Mai 2008</p> <p>11. <i>Ioana Agache</i>; Tratatamentul țintit pe căile respiratorii mici - când, cum și cu ce beneficii – Congresul Societății Naționale de Pneumologie, Poiana Brașov, 2016</p> <p>12. <i>Ioana Agache</i>; Exacerbarea astmatică – endotip și biomarkeri – Congresul Societății Naționale de Pneumologie, Poiana Brașov, 2016</p> <p>13. <i>Ioana Agache</i>; Initial assessment and control of the patient with asthma – Conferința Națională Anuală a Societății Române de Alergologie și Imunologie Clinică, București, 2016</p>

**Candidat**